Document is current
Any future updates will be listed below
-
Authors
Buchbinder, Elizabeth I.
Giobbie-Hurder, Anita
Ott, Patrick A.
- License Information
-
More Information
Article History
Received: 29 March 2023
Accepted: 20 April 2023
First Online: 25 April 2023
Declarations
:
: Ethics approval for the study was obtained through the DF/HCC Institutional Review Board.
: EB has served on advisory boards for Nektar, Instilbio, Novartis, Xilio, Sanofi, Merck and Iovance and received research funding from Lilly, Novartis, Partners therapeutics, Genentech, BMS and BVD.
